See more : elexxion AG (E8X.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Gamida Cell Ltd. (GMDA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gamida Cell Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Guangzheng Eye Hospital Group Co., Ltd. (002524.SZ) Income Statement Analysis – Financial Results
- Romeo Power, Inc. (RMO) Income Statement Analysis – Financial Results
- Annaly Capital Management, Inc. (NLY) Income Statement Analysis – Financial Results
- Nordex SE (NRDXF) Income Statement Analysis – Financial Results
- KOSÉ Corporation (KSRYY) Income Statement Analysis – Financial Results
Gamida Cell Ltd. (GMDA)
About Gamida Cell Ltd.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.48M | 440.00K | 431.00K | 357.00K | 2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.69M | -440.00K | -431.00K | -357.00K | -2.14M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -94.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 22.28M | 42.69M | 50.18M | 41.39M | 31.46M | 22.05M | 15.02M | 19.10M |
| General & Administrative | 44.58M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Selling & Marketing | 4.08M | 12.90K | 20.01K | 8.89K | 4.69K | 0.00 | 0.00 | 0.00 |
| SG&A | 48.67M | 19.40M | 16.98M | 12.17M | 12.09M | 11.60M | 4.47M | 4.61M |
| Other Expenses | -395.00K | 12.90M | 20.01M | 8.75M | 4.69M | 195.00K | -2.27M | 1.81M |
| Operating Expenses | 70.95M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Cost & Expenses | 74.43M | 74.99M | 87.17M | 62.30M | 48.25M | 33.64M | 19.49M | 23.71M |
| Interest Income | 2.73M | 4.38K | 2.63K | 236.00K | 17.15M | 1.04M | 330.00K | 163.00K |
| Interest Expense | 7.59M | 4.38M | 2.63M | 10.64M | 3.33M | 20.26M | 30.00K | 23.00K |
| Depreciation & Amortization | 2.02M | -149.55M | 431.00K | 2.63M | 19.29M | 269.00K | 162.00K | 124.00K |
| EBITDA | -70.62M | -74.55M | -86.74M | -60.57M | -28.95M | -32.60M | -20.16M | -24.48M |
| EBITDA Ratio | -3,958.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -72.64M | 74.99M | -87.17M | -62.30M | -48.25M | -33.64M | -19.49M | -23.71M |
| Operating Income Ratio | -4,071.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.65M | -4.38M | -2.63M | -648.00K | 13.82M | -19.22M | 479.00K | 1.04M |
| Income Before Tax | -63.00M | -79.38M | -89.79M | -72.70M | -34.42M | -52.86M | -19.01M | -22.67M |
| Income Before Tax Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.00 | 74.99M | 2.63M | 3.74M | -70.00K | 70.00K | -479.00K | -1.04M |
| Net Income | -63.00M | -154.37M | -92.42M | -76.45M | -34.35M | -52.93M | -19.01M | -22.67M |
| Net Income Ratio | -3,531.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -2.42 | -1.56 | -1.75 | -1.17 | -10.53 | -1.06 | -1.26 |
| EPS Diluted | -0.57 | -2.42 | -1.56 | -1.75 | -1.16 | -10.53 | -1.06 | -1.26 |
| Weighted Avg Shares Out | 110.05M | 63.83M | 59.25M | 43.73M | 29.46M | 5.03M | 17.97M | 17.97M |
| Weighted Avg Shares Out (Dil) | 110.05M | 63.83M | 59.25M | 43.73M | 29.66M | 5.03M | 17.97M | 17.97M |
Gamida Cell (GMDA) Upgraded to Buy: Here's Why
Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million...
Gamida Cell Announces Closing of $25 Million Financing With Highbridge
BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of...
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming...
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the...
Gamida Cell Provides Regulatory Update on Omidubicel
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration...
Gamida Cell Provides Regulatory Update on Omidubicel
BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and...
Gamida Cell Ltd. (GMDA)Q3 2022 Earnings Call Transcript
Gamida Cell Ltd. (NASDAQ:GMDA ) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Abigail Jenkins - President & CEO Ronit Simantov - CMO & Chief Scientific...
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September...
Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update
BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter...
Source: https://incomestatements.info
Category: Stock Reports